Becton, Dickinson and Co.(BDX)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $140.11 – $213.08
- YTD
- -7.30%
- IV Rank (30D)
- 8.31
- Straddle Price
- $10.80
- P/C Vol Ratio
- 0.06
- Market Cap
- $49.3B
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.94% |
| Beta vs SPY | 0.67 |
| Cost of Equity (CAPM) | 8.31% (VRP-adj) |
| WACC | 7.81% |
| Volatility Risk Premium | +23.4pp (IV − HV30) |
| Effective Tax Rate | 14.2% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 5 years explicit + fade |
| Free Cash Flow (TTM) | $2.5B |
| Return on Equity (TTM) | 3.9% |
| Book / Price | 46.8% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 46.8% |
| FCF Margin (TTM) | 11.9% |
| Debt / Equity | 0.61 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| Market-Implied Growth | +9.3% (reverse-DCF on current price) |
| SMA 50 | $175.37 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $184.52 |
| Bollinger Width / SMA20 | 5.2% (drives anchor stability) |
| Net Debt | $13.9B |
| Market Cap | $52B |
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $47.46 | 16% | |
| DDM (Gordon) | $20.64 | 13% | |
| Peer P/E | $88.99 | 4% | median 22.5× · 5 peers |
| Peer EV/EBITDA | $245.59 | 5% | median 14.4× · 5 peers |
| Peer P/B | $223.11 | 6% | median 2.6× · 5 peers |
| Peer P/S | $234.94 | 6% | median 3.1× · 5 peers |
| Market Anchor (SMA50) | $175.37 | 33% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | $181.91 | 16% | 24 strikes · skew +0.31 |
- Industry (SIC)
- SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841)
- Exchange
- XNYS
- Market Cap
- $49.3B
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United Stat…
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +3.53% | 23 |
| Feb | -1.28% | 23 |
| Mar | +0.15% | 23 |
| Apr | +0.40% | 23 |
| May | -1.29% | 23 |
| Jun | +0.67% | 23 |
| Jul | +2.94% | 23 |
| Aug | +0.44% | 23 |
| Sep | -1.28% | 24 |
| Oct | -0.20% | 23 |
| Nov | +3.45% | 23 |
| Dec | +1.77% | 23 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report: BDX
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers and Primary Risks: Strong technical signals, positive news sentiment, and low volatility are balanced by the absence of earnings data and a relatively high implied volatility.
Investment Thesis: BDX is trading within a neutral range, with a mix of positive and negative indicators. The stock's beta is low, indicating low volatility relative to the market. Recent news headlines suggest a favorable environment for the company, but earnings data would be beneficial to increase confidence in the investment thesis.
Recent News Sentiment Impact: Positive news sentiment from recent headlines has contributed to the neutral assessment, with no significant negative or bearish catalysts present.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Uptrend
- Medium-term (1-3 months): Neutral
- Long-term (3-12 months): Bullish
Support/Resistance Levels: Critical price levels to monitor are:
- Lower resistance: $186.15 (SMA 20)
- Upper support: $178.88 (Lower Bollinger Band)
Momentum Signals:
- RSI: Neutral (46.37)
- MACD: Bullish (4.03 / Signal: -1.84 / Histogram: 5.87)
- Bollinger Bands: Neutral (price touching the middle band)
Volume Analysis: Institutional interest is moderate, with a volume rate of change indicating recent buying pressure.
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines from various industries, including diagnostics and medical devices, have contributed to the neutral assessment.
Sentiment Assessment: Aggregate news sentiment is positive (4/5), with no significant negative or bearish catalysts present.
Catalyst Identification: Upcoming earnings data would be beneficial to increase confidence in the investment thesis. No other notable catalysts are currently scheduled.
Market Narrative: The recent news headlines align with the neutral technical signals, suggesting a favorable environment for BDX.
Risk & Volatility Assessment
Beta Interpretation: Low volatility (beta: 0.39) indicates that the stock moves less than the market.
Volatility Regime: Current volatility is low compared to historical levels.
Options Market Signals: Implied volatility is relatively high, but options activity suggests a balanced mix of buying and selling pressure.
Downside Protection: Support levels are present at $178.88 (Lower Bollinger Band) and $170.46 (SMA 50), with no significant risk management considerations necessary at this time.
Market Context & Positioning
Sector Performance: BDX is trading within its sector's neutral range.
Institutional Activity: Moderate institutional interest is present, with a volume rate of change indicating recent buying pressure.
Correlation Analysis: The stock moves less than the market (beta: 0.39), suggesting low correlation and volatility.
Relative Valuation: Positioning within the trading range suggests that BDX is relatively fairly valued compared to its sector peers.
Key Levels & Action Items
- Critical price levels: $186.15 (SMA 20) and $178.88 (Lower Bollinger Band)
- Breakout/Breakdown levels: $193.43 (Upper Bollinger Band) and $170.46 (SMA 50)
- Time-sensitive catalysts: Earnings data would be beneficial to increase confidence in the investment thesis.
- Risk management: Stop-loss levels should be set at $178.88 (Lower Bollinger Band), with position sizing considerations based on current volatility.
Additional Comments: The analysis is influenced by the absence of earnings data, which reduces confidence in the investment thesis. A more detailed assessment would require additional information about BDX's financial performance and industry trends.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-11-07 | Pre-Market | 5.04% | 5.54% | 1.10x | Exceeded |
| 2025-02-05 | Pre-Market | 4.85% | 3.12% | 0.64x | Within |
| 2025-05-01 | Pre-Market | 6.38% | 17.89% | 2.80x | Exceeded |
| 2025-08-07 | Pre-Market | 7.77% | 8.77% | 1.13x | Exceeded |
| 2025-10-15 | Pre-Market | 2.32% | 0.84% | 0.36x | Within |
| 2026-02-09 | Pre-Market | 7.60% | 1.67% | 0.22x | Within |
| 2026-05-07 | Pre-Market | 6.70% | 5.87% | 0.88x | Within |
| 2026-08-06 | Pre-Market | 7.91% | 4.54% | 0.57x | Within |
- IV Rank (30D)
- 8.31
- IV Rank (7D)
- 8.31
- Avg IV
- 46.5%
- Straddle (30D)
- $10.80
- Straddle (7D)
- $10.80
- P/C Volume
- 0.06
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
- Beta (1Y vs SPY)
- 0.38
- Correlation (SPY)
- 16.1%
- R²
- 0.03
- Ann. Volatility
- 30.8%
- SPY Volatility
- 13.0%
Low volatility - stock moves less than market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | JANE STREET GROUP, LLC Custodian | $48.50M | 35.34% | 2026-06-30 |
| 2 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $35.44M | 25.83% | 2026-06-30 |
| 3 | GOLDMAN SACHS GROUP INC Custodian | $18.90M | 13.77% | 2026-06-30 |
| 4 | CITADEL ADVISORS LLC Custodian | $7.91M | 5.77% | 2026-06-30 |
| 5 | Cubist Systematic Strategies, LLC | $7.36M | 5.36% | 2025-09-30 |
| 6 | WOLVERINE TRADING, LLC Custodian | $7.21M | 5.26% | 2025-09-30 |
| 7 | IMC-Chicago, LLC Custodian | $3.44M | 2.50% | 2026-06-30 |
| 8 | Walleye Capital LLC | $1.82M | 1.32% | 2026-06-30 |
| 9 | SIMPLEX TRADING, LLC Custodian | $1.29M | 0.94% | 2026-06-30 |
| 10 | PEAK6 LLC | $998.78K | 0.73% | 2026-06-30 |
| 11 | Point72 Asset Management, L.P. | $938.25K | 0.68% | 2026-06-30 |
| 12 | Walleye Trading LLC | $771.78K | 0.56% | 2026-06-30 |
| 13 | Qube Research & Technologies Ltd | $635.59K | 0.46% | 2026-06-30 |
| 14 | Allianz Asset Management GmbH | $620.45K | 0.45% | 2026-06-30 |
| 15 | READYSTATE ASSET MANAGEMENT LP | $469.12K | 0.34% | 2026-06-30 |
| 16 | TUDOR INVESTMENT CORP ET AL | $378.32K | 0.28% | 2026-06-30 |
| 17 | Alphadyne Asset Management LP | $227.00K | 0.17% | 2026-06-30 |
| 18 | GROUP ONE TRADING LLC Custodian | $151.33K | 0.11% | 2026-06-30 |
| 19 | Point72 (DIFC) Ltd | $149.74K | 0.11% | 2025-09-30 |
| 20 | Chicago Partners Investment Group LLC | $15.30K | 0.01% | 2026-06-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $33.88M | 38.80% | 2026-06-30 |
| 2 | CITADEL ADVISORS LLC Custodian | $17.84M | 20.43% | 2026-06-30 |
| 3 | JANE STREET GROUP, LLC Custodian | $10.99M | 12.58% | 2026-06-30 |
| 4 | Cubist Systematic Strategies, LLC | $7.69M | 8.81% | 2025-09-30 |
| 5 | WOLVERINE TRADING, LLC Custodian | $4.51M | 5.16% | 2025-09-30 |
| 6 | IMC-Chicago, LLC Custodian | $3.47M | 3.97% | 2026-06-30 |
| 7 | UBS Group AG Custodian | $2.27M | 2.60% | 2026-06-30 |
| 8 | JPMORGAN CHASE & CO Custodian | $1.30M | 1.49% | 2026-06-30 |
| 9 | Allianz Asset Management GmbH | $1.26M | 1.44% | 2026-06-30 |
| 10 | GROUP ONE TRADING LLC Custodian | $1.07M | 1.23% | 2026-06-30 |
| 11 | SIMPLEX TRADING, LLC Custodian | $577.14K | 0.66% | 2026-06-30 |
| 12 | Walleye Capital LLC | $559.92K | 0.64% | 2026-06-30 |
| 13 | CAPSTONE INVESTMENT ADVISORS, LLC | $378.32K | 0.43% | 2026-06-30 |
| 14 | Alphadyne Asset Management LP | $332.93K | 0.38% | 2026-06-30 |
| 15 | Lighthouse Investment Partners, LLC | $302.66K | 0.35% | 2026-06-30 |
| 16 | READYSTATE ASSET MANAGEMENT LP | $287.53K | 0.33% | 2026-06-30 |
| 17 | Lido Advisors, LLC | $272.39K | 0.31% | 2026-06-30 |
| 18 | Walleye Trading LLC | $166.46K | 0.19% | 2026-06-30 |
| 19 | Qube Research & Technologies Ltd | $90.80K | 0.10% | 2026-06-30 |
| 20 | Point72 (DIFC) Ltd | $56.15K | 0.06% | 2025-09-30 |
| 21 | Point72 Asset Management, L.P. | $15.13K | 0.02% | 2026-06-30 |
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-03 | Vitor Roque | EVP & Chief Financial Officer | Tax (F) | −190 | — | EDGAR | |
| 2026-08-27 | Michael Feld | EVP, Chief Revenue Officer | Sell (S) | −165 | $188.49 | -$31.1K | EDGAR |
| 2026-08-24 | Michael Feld | EVP, Chief Revenue Officer | Tax (F) | −1,049 | — | EDGAR | |
| 2026-08-14 | Thomas E Polen Jr | Chairman, CEO and President | Mixed | — | $176.12 | -$768.2K | EDGAR |
| 2026-08-12 | Roland Goette | EVP and President, EMEA | Sell (S) | −2,438 | $180.84 | -$440.9K | EDGAR |
| 2026-08-06 | Robert Luther Huffines | Director | Grant (A) | +189 RSU | — | EDGAR | |
| 2026-08-06 | Carrie L Byington | Director | Grant (A) | +94 RSU | — | EDGAR | |
| 2026-08-06 | Robert Luther Huffines | Director | Grant (A) | +189 RSU | — | EDGAR | |
| 2026-08-06 | Carrie L Byington | Director | Grant (A) | +94 RSU | — | EDGAR | |
| 2026-07-28 | Michael Feld | EVP, Chief Revenue Officer | Sell (S) | −75 | $157.13 | -$11.8K | EDGAR |
| 2026-07-06 | Bilal Muhsin | EVP & President Connected Care | Mixed | +12,407 | — | EDGAR | |
| 2026-06-26 | Michael Feld | EVP, Chief Revenue Officer | Sell (S) | −75 | $152.80 | -$11.5K | EDGAR |
| 2026-06-25 | Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | Sell (S) | −1,100 | $145.66 | -$160.2K | EDGAR |
| 2026-06-11 | Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | Sell (S) | −1,100 | $151.48 | -$166.6K | EDGAR |
| 2026-06-03 | Thomas E Polen Jr | Chairman, CEO and President | Mixed | — | $136.17 | -$404.5K | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | VINCENT A FORLENZA | Chairman, CEO and President | 206,995 | $37.40M | -$30.90M | 33 | 2016-12-23 |
| 2 | HENRY P BECTON JR | Director | 140,311 | $25.35M | -$46.56M | 67 | 2015-11-03 |
| 3 | EDWARD J LUDWIG | Chairman | 135,101 | $24.41M | -$75.58M | 32 | 2012-07-11 |
| 4 | Thomas E Polen Jr | Chairman, CEO and President | 110,163 | $19.91M | -$3.32M | 13 | 2026-08-14 |
| 5 | JOHN R CONSIDINE | Vice Chairman | 96,375 | $17.41M | -$23.77M | 8 | 2009-11-25 |
| 6 | GARY M COHEN | Executive Vice President | 91,944 | $16.61M | -$35.81M | 38 | 2017-01-03 |
| 7 | WILLIAM A KOZY | Executive Vice President | 80,948 | $14.63M | -$26.64M | 32 | 2015-12-09 |
| 8 | TIMOTHY M RING | Director | 61,445 | $11.10M | $0 | 3 | 2026-01-29 |
| 9 | ALFRED JOHN HANSON | Executive Vice President | 50,880 | $9.19M | -$9.88M | 6 | 2008-11-26 |
| 10 | JEFFREY S SHERMAN | Sr. VP and General Counsel | 49,079 | $8.87M | -$20.89M | 34 | 2017-02-16 |
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-26 | MICHAEL FELD | Officer | 165 | $31.3K | 2026-08-26 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-20 | RICHARD BYRD | Former Officer | 1,330 | $250.0K | 2026-08-20 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-13 | THOMAS POLEN | Director, Officer | 4,152 | $762.2K | 2026-08-13 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-11 | Roland Goette | Officer | 2,438 | $440.9K | 2026-08-11 | UBS Securities LLC | — | EDGAR |
| 2026-08-03 | SHANA NEAL | Officer | 1,500 | $248.4K | 2026-08-03 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-27 | MICHAEL FELD | Officer | 75 | $11.7K | 2026-07-27 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-26 | MICHAEL FELD | Officer | 75 | $11.4K | 2026-06-26 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-24 | MICHAEL GARRISON | Officer | 1,100 | $158.3K | 2026-06-24 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-10 | MICHAEL GARRISON | Officer | 1,100 | $167.2K | 2026-06-10 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-01 | THOMAS POLEN | Officer | 2,764 | $406.6K | 2026-06-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-29 | 0001628280-26-039005 | EDGAR |
| 2026-05-20 | 0001140361-26-022270 | EDGAR |
| 2026-05-12 | 0001140361-26-020828 | EDGAR |
| 2026-05-07 | 0001628280-26-031638 | EDGAR |
| 2026-04-29 | 0000010795-26-000012 | EDGAR |
| 2026-04-09 | 0001628280-26-024472 | EDGAR |
| 2026-04-02 | 0001628280-26-023185 | EDGAR |
| 2026-02-25 | 0001140361-26-006794 | EDGAR |
| 2026-02-10 | 0001140361-26-004601 | EDGAR |
| 2026-02-09 | 0001628280-26-006182 | EDGAR |
| Filing Date | Accession | Link |
|---|---|---|
| 2025-11-25 | 0000010795-25-000099 | EDGAR |
| 2024-11-27 | 0000010795-24-000084 | EDGAR |
| 2023-11-21 | 0000010795-23-000098 | EDGAR |
| 2022-11-22 | 0001628280-22-030686 | EDGAR |
| 2021-11-24 | 0000010795-21-000091 | EDGAR |
| 2020-11-25 | 0000010795-20-000055 | EDGAR |
| 2019-11-27 | 0000010795-19-000044 | EDGAR |
| 2018-11-21 | 0000010795-18-000036 | EDGAR |
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-07 | 0000010795-26-000026 | EDGAR |
| 2026-02-09 | 0000010795-26-000005 | EDGAR |
| 2025-08-07 | 0000010795-25-000072 | EDGAR |
| 2025-05-01 | 0000010795-25-000039 | EDGAR |
| 2025-02-06 | 0000010795-25-000022 | EDGAR |
| 2024-08-01 | 0000010795-24-000067 | EDGAR |
| 2024-05-02 | 0000010795-24-000039 | EDGAR |
| 2024-02-01 | 0000010795-24-000019 | EDGAR |
| 2023-08-03 | 0000010795-23-000075 | EDGAR |
| 2023-05-04 | 0000010795-23-000039 | EDGAR |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/E Ratio | 45.7 |
| P/B Ratio | 2.0 |
| P/S Ratio | 2.4 |
| EV/EBITDA | 11.8 |
| TTM Revenue | $21.4B |
| TTM Net Income | $1.1B |
| TTM EPS | $3.95 |
| ROE | 3.9% |
| Dividend Yield | 2.38% |
| Debt/Equity | 0.69 |